Le SIDA en Afrique subsaharienne (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Scaling Up AIDS Treatment in Developing Countries: A Review of Current and Future Arguments

Identifieur interne : 003A25 ( Istex/Corpus ); précédent : 003A24; suivant : 003A26

Scaling Up AIDS Treatment in Developing Countries: A Review of Current and Future Arguments

Auteurs : Jens Kovsted

Source :

RBID : ISTEX:B222C0C037167C7FAED8E8B4C7EA064BCD5EF02F

English descriptors

Abstract

Until recently, antiretroviral treatment against AIDS was perceived to be beyond the reach of the majority of patients in developing countries. This situation has changed drastically as international funding for AIDS treatment has swelled to several billion dollars a year. What has brought about this change? Analysis of the merit of six arguments often put forward against scaling up AIDS treatment in developing countries makes it clear that the most significant (and perhaps only) real change has been the large reduction in the price of the drugs. Although affordability is obviously a central issue, it is noticeable that most of the remaining arguments continue to be unresolved. This underlines the dangers of proceeding too fast towards treatment goals.

Url:
DOI: 10.1111/j.1467-7679.2005.00297.x

Links to Exploration step

ISTEX:B222C0C037167C7FAED8E8B4C7EA064BCD5EF02F

Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Scaling Up AIDS Treatment in Developing Countries: A Review of Current and Future Arguments</title>
<author>
<name sortKey="Kovsted, Jens" sort="Kovsted, Jens" uniqKey="Kovsted J" first="Jens" last="Kovsted">Jens Kovsted</name>
<affiliation>
<mods:affiliation>JKVS@novonordisk.com.</mods:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:B222C0C037167C7FAED8E8B4C7EA064BCD5EF02F</idno>
<date when="2005" year="2005">2005</date>
<idno type="doi">10.1111/j.1467-7679.2005.00297.x</idno>
<idno type="url">https://api.istex.fr/document/B222C0C037167C7FAED8E8B4C7EA064BCD5EF02F/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">003A25</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">003A25</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main">Scaling Up AIDS Treatment in Developing Countries: A Review of Current and Future Arguments</title>
<author>
<name sortKey="Kovsted, Jens" sort="Kovsted, Jens" uniqKey="Kovsted J" first="Jens" last="Kovsted">Jens Kovsted</name>
<affiliation>
<mods:affiliation>JKVS@novonordisk.com.</mods:affiliation>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j" type="main">Development Policy Review</title>
<title level="j" type="alt">DEVELOPMENT POLICY REVIEW</title>
<idno type="ISSN">0950-6764</idno>
<idno type="eISSN">1467-7679</idno>
<imprint>
<biblScope unit="vol">23</biblScope>
<biblScope unit="issue">4</biblScope>
<biblScope unit="page" from="465">465</biblScope>
<biblScope unit="page" to="482">482</biblScope>
<biblScope unit="page-count">18</biblScope>
<publisher>Blackwell Publishing Ltd</publisher>
<pubPlace>Oxford, UK</pubPlace>
<date type="published" when="2005-07">2005-07</date>
</imprint>
<idno type="ISSN">0950-6764</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0950-6764</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Absolute costs</term>
<term>Absolute prices</term>
<term>Active antiretroviral therapy</term>
<term>Active antiretroviral treatment</term>
<term>Aids activists</term>
<term>Aids exceptionalism</term>
<term>Aids treatment</term>
<term>Antiretroviral</term>
<term>Antiretroviral therapy</term>
<term>Antiretroviral treatment</term>
<term>Cape town</term>
<term>Central issue</term>
<term>Chronic disease</term>
<term>Country governments</term>
<term>Current level</term>
<term>Domestic governments</term>
<term>Economic pragmatists</term>
<term>Evidential base</term>
<term>Expensive treatment</term>
<term>First glance</term>
<term>Funding</term>
<term>Future rounds</term>
<term>Global</term>
<term>Global fund</term>
<term>Guideline</term>
<term>Haart</term>
<term>Haart drugs</term>
<term>Haart programmes</term>
<term>Haart treatment</term>
<term>Health emergency</term>
<term>Health sector</term>
<term>Health staff</term>
<term>Health workers</term>
<term>Heterosexual transmission</term>
<term>High level</term>
<term>Human immunodeficiency virus type</term>
<term>Human rights</term>
<term>Immune deficiency syndrome</term>
<term>Infrastructure</term>
<term>International agencies</term>
<term>International development</term>
<term>International organisations</term>
<term>International resources</term>
<term>Jens</term>
<term>Jens kovsted</term>
<term>Kovsted</term>
<term>Lancet</term>
<term>Large extent</term>
<term>Large reduction</term>
<term>Long latency period</term>
<term>Many countries</term>
<term>Media attention</term>
<term>Media interest</term>
<term>Nattrass</term>
<term>Oecd</term>
<term>Oecd countries</term>
<term>Organisation</term>
<term>Other hand</term>
<term>Other health interventions</term>
<term>Pharmaceutical companies</term>
<term>Pilot projects</term>
<term>Poor adherence</term>
<term>Poorer countries</term>
<term>Positive externalities</term>
<term>Programme</term>
<term>Public health</term>
<term>Public health sector</term>
<term>Real change</term>
<term>Regimen</term>
<term>Resistant strains</term>
<term>Risk behaviour</term>
<term>Scarce resources</term>
<term>Social science research</term>
<term>Success rate</term>
<term>Technical assistance</term>
<term>Total budget</term>
<term>Total costs</term>
<term>Treatment advocates</term>
<term>Treatment paradigm</term>
<term>Unaids</term>
<term>Unavoidable consequence</term>
<term>Unique opportunity</term>
<term>Viral load</term>
<term>Widespread testing</term>
<term>World bank</term>
<term>World health organisation</term>
<term>World health organization</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en">
<term>Absolute costs</term>
<term>Absolute prices</term>
<term>Active antiretroviral therapy</term>
<term>Active antiretroviral treatment</term>
<term>Aids activists</term>
<term>Aids exceptionalism</term>
<term>Aids treatment</term>
<term>Antiretroviral</term>
<term>Antiretroviral therapy</term>
<term>Antiretroviral treatment</term>
<term>Cape town</term>
<term>Central issue</term>
<term>Chronic disease</term>
<term>Country governments</term>
<term>Current level</term>
<term>Domestic governments</term>
<term>Economic pragmatists</term>
<term>Evidential base</term>
<term>Expensive treatment</term>
<term>First glance</term>
<term>Funding</term>
<term>Future rounds</term>
<term>Global</term>
<term>Global fund</term>
<term>Guideline</term>
<term>Haart</term>
<term>Haart drugs</term>
<term>Haart programmes</term>
<term>Haart treatment</term>
<term>Health emergency</term>
<term>Health sector</term>
<term>Health staff</term>
<term>Health workers</term>
<term>Heterosexual transmission</term>
<term>High level</term>
<term>Human immunodeficiency virus type</term>
<term>Human rights</term>
<term>Immune deficiency syndrome</term>
<term>Infrastructure</term>
<term>International agencies</term>
<term>International development</term>
<term>International organisations</term>
<term>International resources</term>
<term>Jens</term>
<term>Jens kovsted</term>
<term>Kovsted</term>
<term>Lancet</term>
<term>Large extent</term>
<term>Large reduction</term>
<term>Long latency period</term>
<term>Many countries</term>
<term>Media attention</term>
<term>Media interest</term>
<term>Nattrass</term>
<term>Oecd</term>
<term>Oecd countries</term>
<term>Organisation</term>
<term>Other hand</term>
<term>Other health interventions</term>
<term>Pharmaceutical companies</term>
<term>Pilot projects</term>
<term>Poor adherence</term>
<term>Poorer countries</term>
<term>Positive externalities</term>
<term>Programme</term>
<term>Public health</term>
<term>Public health sector</term>
<term>Real change</term>
<term>Regimen</term>
<term>Resistant strains</term>
<term>Risk behaviour</term>
<term>Scarce resources</term>
<term>Social science research</term>
<term>Success rate</term>
<term>Technical assistance</term>
<term>Total budget</term>
<term>Total costs</term>
<term>Treatment advocates</term>
<term>Treatment paradigm</term>
<term>Unaids</term>
<term>Unavoidable consequence</term>
<term>Unique opportunity</term>
<term>Viral load</term>
<term>Widespread testing</term>
<term>World bank</term>
<term>World health organisation</term>
<term>World health organization</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Until recently, antiretroviral treatment against AIDS was perceived to be beyond the reach of the majority of patients in developing countries. This situation has changed drastically as international funding for AIDS treatment has swelled to several billion dollars a year. What has brought about this change? Analysis of the merit of six arguments often put forward against scaling up AIDS treatment in developing countries makes it clear that the most significant (and perhaps only) real change has been the large reduction in the price of the drugs. Although affordability is obviously a central issue, it is noticeable that most of the remaining arguments continue to be unresolved. This underlines the dangers of proceeding too fast towards treatment goals.</div>
</front>
</TEI>
<istex>
<corpusName>wiley</corpusName>
<keywords>
<teeft>
<json:string>haart</json:string>
<json:string>antiretroviral</json:string>
<json:string>oecd</json:string>
<json:string>unaids</json:string>
<json:string>programme</json:string>
<json:string>aids treatment</json:string>
<json:string>guideline</json:string>
<json:string>kovsted</json:string>
<json:string>infrastructure</json:string>
<json:string>global fund</json:string>
<json:string>health workers</json:string>
<json:string>organisation</json:string>
<json:string>lancet</json:string>
<json:string>funding</json:string>
<json:string>nattrass</json:string>
<json:string>antiretroviral treatment</json:string>
<json:string>oecd countries</json:string>
<json:string>haart treatment</json:string>
<json:string>cape town</json:string>
<json:string>risk behaviour</json:string>
<json:string>world bank</json:string>
<json:string>pharmaceutical companies</json:string>
<json:string>jens</json:string>
<json:string>regimen</json:string>
<json:string>haart drugs</json:string>
<json:string>economic pragmatists</json:string>
<json:string>aids activists</json:string>
<json:string>human rights</json:string>
<json:string>public health</json:string>
<json:string>international agencies</json:string>
<json:string>total costs</json:string>
<json:string>widespread testing</json:string>
<json:string>domestic governments</json:string>
<json:string>social science research</json:string>
<json:string>international organisations</json:string>
<json:string>media attention</json:string>
<json:string>world health organisation</json:string>
<json:string>media interest</json:string>
<json:string>international development</json:string>
<json:string>antiretroviral therapy</json:string>
<json:string>high level</json:string>
<json:string>active antiretroviral therapy</json:string>
<json:string>many countries</json:string>
<json:string>heterosexual transmission</json:string>
<json:string>absolute prices</json:string>
<json:string>jens kovsted</json:string>
<json:string>absolute costs</json:string>
<json:string>expensive treatment</json:string>
<json:string>pilot projects</json:string>
<json:string>aids exceptionalism</json:string>
<json:string>poorer countries</json:string>
<json:string>health sector</json:string>
<json:string>long latency period</json:string>
<json:string>haart programmes</json:string>
<json:string>public health sector</json:string>
<json:string>treatment paradigm</json:string>
<json:string>chronic disease</json:string>
<json:string>positive externalities</json:string>
<json:string>first glance</json:string>
<json:string>large extent</json:string>
<json:string>other hand</json:string>
<json:string>viral load</json:string>
<json:string>treatment advocates</json:string>
<json:string>unavoidable consequence</json:string>
<json:string>total budget</json:string>
<json:string>real change</json:string>
<json:string>health emergency</json:string>
<json:string>technical assistance</json:string>
<json:string>success rate</json:string>
<json:string>human immunodeficiency virus type</json:string>
<json:string>resistant strains</json:string>
<json:string>future rounds</json:string>
<json:string>current level</json:string>
<json:string>scarce resources</json:string>
<json:string>international resources</json:string>
<json:string>unique opportunity</json:string>
<json:string>other health interventions</json:string>
<json:string>country governments</json:string>
<json:string>health staff</json:string>
<json:string>immune deficiency syndrome</json:string>
<json:string>evidential base</json:string>
<json:string>world health organization</json:string>
<json:string>active antiretroviral treatment</json:string>
<json:string>central issue</json:string>
<json:string>large reduction</json:string>
<json:string>poor adherence</json:string>
<json:string>global</json:string>
<json:string>behaviour</json:string>
</teeft>
</keywords>
<author>
<json:item>
<name>Jens Kovsted</name>
<affiliations>
<json:string>JKVS@novonordisk.com.</json:string>
</affiliations>
</json:item>
</author>
<articleId>
<json:string>DPR297</json:string>
</articleId>
<language>
<json:string>eng</json:string>
</language>
<originalGenre>
<json:string>article</json:string>
</originalGenre>
<abstract>Until recently, antiretroviral treatment against AIDS was perceived to be beyond the reach of the majority of patients in developing countries. This situation has changed drastically as international funding for AIDS treatment has swelled to several billion dollars a year. What has brought about this change? Analysis of the merit of six arguments often put forward against scaling up AIDS treatment in developing countries makes it clear that the most significant (and perhaps only) real change has been the large reduction in the price of the drugs. Although affordability is obviously a central issue, it is noticeable that most of the remaining arguments continue to be unresolved. This underlines the dangers of proceeding too fast towards treatment goals.</abstract>
<qualityIndicators>
<score>6.416</score>
<pdfVersion>1.3</pdfVersion>
<pdfPageSize>492.112 x 719.744 pts</pdfPageSize>
<refBibsNative>true</refBibsNative>
<abstractCharCount>762</abstractCharCount>
<pdfWordCount>8644</pdfWordCount>
<pdfCharCount>51737</pdfCharCount>
<pdfPageCount>18</pdfPageCount>
<abstractWordCount>118</abstractWordCount>
</qualityIndicators>
<title>Scaling Up AIDS Treatment in Developing Countries: A Review of Current and Future Arguments</title>
<genre>
<json:string>article</json:string>
</genre>
<host>
<title>Development Policy Review</title>
<language>
<json:string>unknown</json:string>
</language>
<doi>
<json:string>10.1111/(ISSN)1467-7679</json:string>
</doi>
<issn>
<json:string>0950-6764</json:string>
</issn>
<eissn>
<json:string>1467-7679</json:string>
</eissn>
<publisherId>
<json:string>DPR</json:string>
</publisherId>
<volume>23</volume>
<issue>4</issue>
<pages>
<first>465</first>
<last>482</last>
<total>18</total>
</pages>
<genre>
<json:string>journal</json:string>
</genre>
</host>
<categories>
<wos>
<json:string>social science</json:string>
<json:string>planning & development</json:string>
</wos>
<scienceMetrix>
<json:string>economic & social sciences</json:string>
<json:string>economics & business </json:string>
<json:string>development studies</json:string>
</scienceMetrix>
<inist>
<json:string>sciences humaines et sociales</json:string>
</inist>
</categories>
<publicationDate>2005</publicationDate>
<copyrightDate>2005</copyrightDate>
<doi>
<json:string>10.1111/j.1467-7679.2005.00297.x</json:string>
</doi>
<id>B222C0C037167C7FAED8E8B4C7EA064BCD5EF02F</id>
<score>1</score>
<fulltext>
<json:item>
<extension>pdf</extension>
<original>true</original>
<mimetype>application/pdf</mimetype>
<uri>https://api.istex.fr/document/B222C0C037167C7FAED8E8B4C7EA064BCD5EF02F/fulltext/pdf</uri>
</json:item>
<json:item>
<extension>zip</extension>
<original>false</original>
<mimetype>application/zip</mimetype>
<uri>https://api.istex.fr/document/B222C0C037167C7FAED8E8B4C7EA064BCD5EF02F/fulltext/zip</uri>
</json:item>
<istex:fulltextTEI uri="https://api.istex.fr/document/B222C0C037167C7FAED8E8B4C7EA064BCD5EF02F/fulltext/tei">
<teiHeader>
<fileDesc>
<titleStmt>
<title level="a" type="main">Scaling Up AIDS Treatment in Developing Countries: A Review of Current and Future Arguments</title>
</titleStmt>
<publicationStmt>
<authority>ISTEX</authority>
<publisher>Blackwell Publishing Ltd</publisher>
<pubPlace>Oxford, UK</pubPlace>
<date type="published" when="2005-07"></date>
</publicationStmt>
<notesStmt>
<note type="content-type" subtype="article" source="article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</note>
<note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note>
</notesStmt>
<sourceDesc>
<biblStruct type="article">
<analytic>
<title level="a" type="main">Scaling Up AIDS Treatment in Developing Countries: A Review of Current and Future Arguments</title>
<author xml:id="author-0000">
<persName>
<forename type="first">Jens</forename>
<surname>Kovsted</surname>
</persName>
<affiliation>JKVS@novonordisk.com.</affiliation>
<email>JKVS@novonordisk.com</email>
<note type="foot">This article was begun while the author was working at the Institute of Economics, University of Copenhagen. The viewpoints contained therein are those of the author and do not in any way represent the viewpoints of Novo Nordisk Inc., DK‐2880 Bagsværd, Denmark. Valuable comments and suggestions by Poul Birch Eriksen and financial support from the Danish Council of Development Research are gratefully acknowledged.</note>
</author>
<idno type="istex">B222C0C037167C7FAED8E8B4C7EA064BCD5EF02F</idno>
<idno type="ark">ark:/67375/WNG-VPG106NP-V</idno>
<idno type="DOI">10.1111/j.1467-7679.2005.00297.x</idno>
<idno type="unit">DPR297</idno>
<idno type="toTypesetVersion">file:DPR.DPR297.pdf</idno>
</analytic>
<monogr>
<title level="j" type="main">Development Policy Review</title>
<title level="j" type="alt">DEVELOPMENT POLICY REVIEW</title>
<idno type="pISSN">0950-6764</idno>
<idno type="eISSN">1467-7679</idno>
<idno type="book-DOI">10.1111/(ISSN)1467-7679</idno>
<idno type="book-part-DOI">10.1111/dpr.2005.23.issue-4</idno>
<idno type="product">DPR</idno>
<idno type="publisherDivision">ST</idno>
<imprint>
<biblScope unit="vol">23</biblScope>
<biblScope unit="issue">4</biblScope>
<biblScope unit="page" from="465">465</biblScope>
<biblScope unit="page" to="482">482</biblScope>
<biblScope unit="page-count">18</biblScope>
<publisher>Blackwell Publishing Ltd</publisher>
<pubPlace>Oxford, UK</pubPlace>
<date type="published" when="2005-07"></date>
</imprint>
</monogr>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<abstract xml:lang="en" style="main">
<p>Until recently, antiretroviral treatment against AIDS was perceived to be beyond the reach of the majority of patients in developing countries. This situation has changed drastically as international funding for AIDS treatment has swelled to several billion dollars a year. What has brought about this change? Analysis of the merit of six arguments often put forward against scaling up AIDS treatment in developing countries makes it clear that the most significant (and perhaps only) real change has been the large reduction in the price of the drugs. Although affordability is obviously a central issue, it is noticeable that most of the remaining arguments continue to be unresolved. This underlines the dangers of proceeding too fast towards treatment goals.</p>
</abstract>
<textClass>
<keywords rend="tocHeading1">
<term>Original Articles</term>
</keywords>
</textClass>
<langUsage>
<language ident="en"></language>
</langUsage>
</profileDesc>
</teiHeader>
</istex:fulltextTEI>
<json:item>
<extension>txt</extension>
<original>false</original>
<mimetype>text/plain</mimetype>
<uri>https://api.istex.fr/document/B222C0C037167C7FAED8E8B4C7EA064BCD5EF02F/fulltext/txt</uri>
</json:item>
</fulltext>
<metadata>
<istex:metadataXml wicri:clean="Wiley, elements deleted: body">
<istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration>
<istex:document>
<component version="2.0" type="serialArticle" xml:lang="en">
<header>
<publicationMeta level="product">
<publisherInfo>
<publisherName>Blackwell Publishing Ltd</publisherName>
<publisherLoc>Oxford, UK</publisherLoc>
</publisherInfo>
<doi origin="wiley" registered="yes">10.1111/(ISSN)1467-7679</doi>
<issn type="print">0950-6764</issn>
<issn type="electronic">1467-7679</issn>
<idGroup>
<id type="product" value="DPR"></id>
<id type="publisherDivision" value="ST"></id>
</idGroup>
<titleGroup>
<title type="main" sort="DEVELOPMENT POLICY REVIEW">Development Policy Review</title>
</titleGroup>
</publicationMeta>
<publicationMeta level="part" position="07104">
<doi origin="wiley">10.1111/dpr.2005.23.issue-4</doi>
<numberingGroup>
<numbering type="journalVolume" number="23">23</numbering>
<numbering type="journalIssue" number="4">4</numbering>
</numberingGroup>
<coverDate startDate="2005-07">July 2005</coverDate>
</publicationMeta>
<publicationMeta level="unit" type="article" position="3" status="forIssue">
<doi origin="wiley">10.1111/j.1467-7679.2005.00297.x</doi>
<idGroup>
<id type="unit" value="DPR297"></id>
</idGroup>
<countGroup>
<count type="pageTotal" number="18"></count>
</countGroup>
<titleGroup>
<title type="tocHeading1">Original Articles</title>
</titleGroup>
<eventGroup>
<event type="firstOnline" date="2005-06-21"></event>
<event type="publishedOnlineFinalForm" date="2005-06-21"></event>
<event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.23 mode:FullText" date="2010-10-19"></event>
<event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-17"></event>
<event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-16"></event>
</eventGroup>
<numberingGroup>
<numbering type="pageFirst" number="465">465</numbering>
<numbering type="pageLast" number="482">482</numbering>
</numberingGroup>
<linkGroup>
<link type="toTypesetVersion" href="file:DPR.DPR297.pdf"></link>
</linkGroup>
</publicationMeta>
<contentMeta>
<unparsedEditorialHistory>first submitted October 2004; final revision accepted April 2005</unparsedEditorialHistory>
<countGroup>
<count type="referenceTotal" number="52"></count>
<count type="linksCrossRef" number="2"></count>
</countGroup>
<titleGroup>
<title type="main">Scaling Up AIDS Treatment in Developing Countries: A Review of Current and Future Arguments</title>
</titleGroup>
<creators>
<creator creatorRole="author" xml:id="cr1" affiliationRef="#a1" noteRef="#fn1">
<personName>
<givenNames>Jens</givenNames>
<familyName>Kovsted</familyName>
</personName>
</creator>
</creators>
<affiliationGroup>
<affiliation xml:id="a1">
<unparsedAffiliation>
<email>JKVS@novonordisk.com</email>
.</unparsedAffiliation>
</affiliation>
</affiliationGroup>
<abstractGroup>
<abstract type="main" xml:lang="en">
<p>Until recently, antiretroviral treatment against AIDS was perceived to be beyond the reach of the majority of patients in developing countries. This situation has changed drastically as international funding for AIDS treatment has swelled to several billion dollars a year. What has brought about this change? Analysis of the merit of six arguments often put forward against scaling up AIDS treatment in developing countries makes it clear that the most significant (and perhaps only) real change has been the large reduction in the price of the drugs. Although affordability is obviously a central issue, it is noticeable that most of the remaining arguments continue to be unresolved. This underlines the dangers of proceeding too fast towards treatment goals.</p>
</abstract>
</abstractGroup>
</contentMeta>
<noteGroup>
<note xml:id="fn1">
<p>This article was begun while the author was working at the Institute of Economics, University of Copenhagen. The viewpoints contained therein are those of the author and do not in any way represent the viewpoints of Novo Nordisk Inc., DK‐2880 Bagsværd, Denmark. Valuable comments and suggestions by Poul Birch Eriksen and financial support from the Danish Council of Development Research are gratefully acknowledged.</p>
</note>
</noteGroup>
</header>
</component>
</istex:document>
</istex:metadataXml>
<mods version="3.6">
<titleInfo lang="en">
<title>Scaling Up AIDS Treatment in Developing Countries: A Review of Current and Future Arguments</title>
</titleInfo>
<titleInfo type="alternative" contentType="CDATA" lang="en">
<title>Scaling Up AIDS Treatment in Developing Countries: A Review of Current and Future Arguments</title>
</titleInfo>
<name type="personal">
<namePart type="given">Jens</namePart>
<namePart type="family">Kovsted</namePart>
<affiliation>JKVS@novonordisk.com.</affiliation>
<description>This article was begun while the author was working at the Institute of Economics, University of Copenhagen. The viewpoints contained therein are those of the author and do not in any way represent the viewpoints of Novo Nordisk Inc., DK‐2880 Bagsværd, Denmark. Valuable comments and suggestions by Poul Birch Eriksen and financial support from the Danish Council of Development Research are gratefully acknowledged.</description>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<typeOfResource>text</typeOfResource>
<genre type="article" displayLabel="article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</genre>
<originInfo>
<publisher>Blackwell Publishing Ltd</publisher>
<place>
<placeTerm type="text">Oxford, UK</placeTerm>
</place>
<dateIssued encoding="w3cdtf">2005-07</dateIssued>
<edition>first submitted October 2004; final revision accepted April 2005</edition>
<copyrightDate encoding="w3cdtf">2005</copyrightDate>
</originInfo>
<language>
<languageTerm type="code" authority="rfc3066">en</languageTerm>
<languageTerm type="code" authority="iso639-2b">eng</languageTerm>
</language>
<physicalDescription>
<extent unit="references">52</extent>
<extent unit="linksCrossRef">2</extent>
</physicalDescription>
<abstract lang="en">Until recently, antiretroviral treatment against AIDS was perceived to be beyond the reach of the majority of patients in developing countries. This situation has changed drastically as international funding for AIDS treatment has swelled to several billion dollars a year. What has brought about this change? Analysis of the merit of six arguments often put forward against scaling up AIDS treatment in developing countries makes it clear that the most significant (and perhaps only) real change has been the large reduction in the price of the drugs. Although affordability is obviously a central issue, it is noticeable that most of the remaining arguments continue to be unresolved. This underlines the dangers of proceeding too fast towards treatment goals.</abstract>
<relatedItem type="host">
<titleInfo>
<title>Development Policy Review</title>
</titleInfo>
<genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre>
<identifier type="ISSN">0950-6764</identifier>
<identifier type="eISSN">1467-7679</identifier>
<identifier type="DOI">10.1111/(ISSN)1467-7679</identifier>
<identifier type="PublisherID">DPR</identifier>
<part>
<date>2005</date>
<detail type="volume">
<caption>vol.</caption>
<number>23</number>
</detail>
<detail type="issue">
<caption>no.</caption>
<number>4</number>
</detail>
<extent unit="pages">
<start>465</start>
<end>482</end>
<total>18</total>
</extent>
</part>
</relatedItem>
<identifier type="istex">B222C0C037167C7FAED8E8B4C7EA064BCD5EF02F</identifier>
<identifier type="ark">ark:/67375/WNG-VPG106NP-V</identifier>
<identifier type="DOI">10.1111/j.1467-7679.2005.00297.x</identifier>
<identifier type="ArticleID">DPR297</identifier>
<recordInfo>
<recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource>
<recordOrigin>Blackwell Publishing Ltd</recordOrigin>
</recordInfo>
</mods>
<json:item>
<extension>json</extension>
<original>false</original>
<mimetype>application/json</mimetype>
<uri>https://api.istex.fr/document/B222C0C037167C7FAED8E8B4C7EA064BCD5EF02F/metadata/json</uri>
</json:item>
</metadata>
<serie></serie>
</istex>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003A25 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 003A25 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    SidaSubSaharaV1
   |flux=    Istex
   |étape=   Corpus
   |type=    RBID
   |clé=     ISTEX:B222C0C037167C7FAED8E8B4C7EA064BCD5EF02F
   |texte=   Scaling Up AIDS Treatment in Developing Countries: A Review of Current and Future Arguments
}}

Wicri

This area was generated with Dilib version V0.6.32.
Data generation: Mon Nov 13 19:31:10 2017. Site generation: Wed Mar 6 19:14:32 2024